“In Silico Dreams: How Artificial Intelligence and Biotechnology will Create the Medicines of the Future”
Abstract
Introduction“In Silico Dreams: How Artificial Intelligence and Biotechnology will Create the Medicines of the Future” is authored by Brian Hilbush whose education in biosciences and career in the biotechnology and pharmaceutical sectors (developing and commercialising emerging and next-generation biotechnologies) offers significant insight into the application of bioinformatics (‘gold’ biotechnology) to understand and solve biological issues using computational techniques.The book opens with a brief introduction setting the scene for what follows, including a brief overview of the book. This is followed by eight chapters that delve into aspects of this field. The first four chapters examine the science and engineering underpinning the field, while the second four chapters look towards the future. Science and Engineering Chapter 1, ‘The Information Revolution’s Impact on Biology’, offers an overview of significant milestones in technology development, highlighting the scientific discipline (for example biology, chemistry, computing and physics) underpinning the technology and how that is woven into the book’s content. This is followed by examples of in silico approaches to ‘omics’ and structural/systems biology, laying the foundations for the subsequent chapters. Chapter 2, ‘A New Era of Artificial Intelligence’, discusses artificial intelligence (AI) and deep or machine learning, highlighting different approaches to machine learning, neural network design concepts and deep…
How strong is the evidence?
Evidence Hub reads this as a simulation / modelling, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.